growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-12. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
26 October In two studies, scientists report findings about the role of epigenetics – which is shaped during lifetime – in colorectal cancer, including that it is a major component of how an individual tumor varies and findings about its influences on the accumulation of DNA mutations and cancer phenotypes. At the 30th anniversary of the World Scientists' Warning to Humanity, scientists conclude that "We are now at 'code red' on planet Earth", facing a climate emergency, warning citizens and world leaders to take necessary actions with information about tracked "recent climate-related disasters, assess[ed] planetary vital signs, and [...] policy recommendations". A study concludes that cosmic radiation events in the tree-ring radiocarbon record called "Miyake events", don't appear to be caused by the solar cycle (i.e. solar flares) as thought previously and have extended durations. They occurred every ~1,000 years on average and may threaten global technologies this century. A magnetical guidance system with engineered bacterial microbots (see also 22 September above) for 'precision targeting' is demonstrated to be effective for fighting cancer in mice. 31 October Multiple traces of monkeypox are detected in non-sewered wastewater with sparse sampling from a densely populated metropolitan area in Asia. A new record for the longest-frozen embryos to ever result in a live birth is reported in the United States, with twins born after storage for 30 years.
== Somatostatin receptor antagonists in radiolabelling == These compounds work by binding to somatostatin receptors, which are more common in specific types of tumours. It does not activate the receptor. Due to the radionuclide, it will appear on PET scans. The radiolabeled somatostatin receptor antagonists share the following structure. The antagonist has a peptide moiety, and is responsible for receptor recognition and antagonist activities. Nomenclature is based on Radionuclide-Chelator-Receptor Antagonist.
Just Stop Oil protesters vandalise Stonehenge by spraying the megaliths with orange cornflour powder paint. A police officer working as part of the prime minister's close protection team is suspended and later arrested as part of an ongoing investigation into bets on the date of the general election. BBC News reports that Laura Saunders, the Conservative candidate for Bristol North West, has become the second Conservative candidate to face an investigation by the Gambling Commission over betting on the date of the general election. It is subsequently reported that her husband, Tony Lee, the Conservative Party's campaigns director, is also being investigated by the commission. 20 June The Bank of England holds interest rates at 5.25%, its seventh consecutive freeze. Sunak says he is "incredibly angry" to learn of allegations that members of his party have betted on the date of the election, and that he will "boot out" anyone found to have broken the law. The number of people becoming ill from a recent outbreak of E. coli across the UK reaches 256, which includes 86 hospitalisations. The UK Health Security Agency reports that case numbers have now slowed, and that everything possible is being done to find the root cause, which may be pre-packaged sandwiches containing lettuce. 21 June Nigel Farage tells the BBC that he believes the Russo-Ukrainian War to have been precipitated by the West's eastward expansion of NATO and the European Union, but that the war itself is Vladimir Putin's fault.
4-Hydroxyphenylglycine (HPG) is a non-proteogenic amino acid found in vancomycin and related glycopeptides. HPG is synthesized from the shikimic acid pathway and requires four enzymes to synthesize: Both L- and D-HPG are used in the vancomycin class of antibiotics. Tyrosine, a similar amino acid, differs by a methylene group (CH2) between the aromatic ring and the alpha carbon.
Sources: en.wikipedia.org
=== Valve Corporation v. Activision Blizzard === In April 2009, Valve sued Activision Blizzard, which acquired Sierra Entertainment after a merger with its parent company, Vivendi Universal Games. Activision had allegedly refused to honor the Valve v. Vivendi arbitration agreement. Activision had only paid Valve $1,967,796 of the $2,391,932 award, refusing to pay the remaining $424,136, claiming it had overpaid that sum in the past years.
The hypothalamus uses dopamine as a prolactostatin to tell the pituitary to inhibit prolactin; it is also created elsewhere in the brain and the adrenal cortex as a neurotransmitter to affect many other systems. The hypothalamus uses RFRP-3 in mammals or GnIH in avian species to inhibit GnRH. The hypothalamus uses follistatin to tell the pituitary to inhibit follicle-stimulating hormone; it also has many other systemic effects. Myocytes use myostatin to tell each other to inhibit myogenesis. Melanocyte-inhibiting factor (melanostatin) inhibits release of other neuropeptides such as alpha-MSH and also has many other functions. There is a neuropeptide called cortistatin and a class of steroidal cortistatins. Examples of releasing and inhibiting hormones for exocrine hormones are gastrin-releasing peptide (GRP) and gastric inhibitory polypeptide (GIP), which regulate gastrin production.
==== Endogenous ==== Endogenous pyrogens are cytokines released from monocytes (which are part of the immune system). In general, they stimulate chemical responses, often in the presence of an antigen, leading to a fever. Whilst they can be a product of external factors like exogenous pyrogens, they can also be induced by internal factors like damage associated molecular patterns such as cases like rheumatoid arthritis or lupus. Major endogenous pyrogens are interleukin 1 (α and β) and interleukin 6 (IL-6). Minor endogenous pyrogens include interleukin-8, tumor necrosis factor-β, macrophage inflammatory protein-α and macrophage inflammatory protein-β as well as interferon-α, interferon-β, and interferon-γ. Tumor necrosis factor-α (TNF) also acts as a pyrogen, mediated by interleukin 1 (IL-1) release. These cytokine factors are released into general circulation, where they migrate to the brain's circumventricular organs where they are more easily absorbed than in areas protected by the blood–brain barrier. The cytokines then bind to endothelial receptors on vessel walls to receptors on microglial cells, resulting in activation of the arachidonic acid pathway. Of these, IL-1β, TNF, and IL-6 are able to raise the temperature setpoint of an organism and cause fever. These proteins produce a cyclooxygenase which induces the hypothalamic production of PGE2 which then stimulates the release of neurotransmitters such as cyclic adenosine monophosphate and increases body temperature.
=== Signs of injury === Stretching for too long or too much can give way to an injury. For most activities, the normal range of motion is more than adequate. Any sudden movements or going too fast can cause a muscle to tighten. This leads to extreme pain and the performer should let the muscle relax by resting.
During anaerobic exercise, the process of glycolysis breaks down the sugars from carbohydrates for energy without the use of oxygen. This type of exercise occurs in physical activity such as power sprints, strength resistances and quick explosive movement where the muscles are being used for power and speed, with short-time energy use. After this type of exercise, there is a need to refill glycogen storage sites in the body (the long simple sugar chains in the body that store energy), although they are not likely fully depleted. To compensate for this glycogen reduction, athletes will often take in large amounts of carbohydrates, immediately following their exercise. Typically, high-glycemic-index carbohydrates are preferred for their ability to rapidly raise blood glucose levels. For the purpose of protein synthesis, protein or individual amino acids are ingested as well. Branched-chain amino acids are important since they are most responsible for the synthesis of protein. According to Lemon et al. (1995) female endurance runners have the hardest time getting enough protein in their diet. Endurance athletes in general need more protein in their diet than the sedentary person. Research has shown that endurance athletes are recommended to have 1.2 to 1.4 g of protein per kg of body weight in order to repair damaged tissue. If the athlete consumes too few calories for the body's needs, lean tissue will be broken down for energy and repair. Protein deficiency can cause many problems such as early and extreme fatigue, particularly long recovery, and poor wound healing.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.